Furthermore, we identified myocardin downregulation as a key mechanism of cardiac insulin resistance mediated by decreasing IRS-1 expression, highlighting the therapeutic potential of upregulating myocardin activity for lipodystrophy cardiomyopathy and insulin resistance-related HF. The gene discussed is MYOCD; the disease is Insulin resistance.